Shield Therapeutics Awarded Company of the Year at the 2016 Bionow Awards

25 Nov 2016

Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that it has been awarded ‘Company of the Year’ at the 2016 Bionow Annual Awards.

Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: “We are honoured to have won the Bionow Company of the Year Award. This is recognition of the progress Shield Therapeutics has made over the past 12 months, which has been an incredible period for the Company, initiated by the completion of our IPO on AIM in February when we successfully raised £32.5m and receipt of a European Marketing Authorisation for Feraccru® – a treatment indicated in adults for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease – which has allowed us to begin commercialisation in Europe, meaning the Company is now one of a select group of revenue producing specialty pharma companies in the UK. This award not only recognises these achievements, but is a significant recognition for the staff at Shield Therapeutics whose tireless work and professionalism has delivered this success. I would like to thank them and we look forward to continuing to build on this success into 2017 and beyond.”

With around 1000 life science and healthcare companies and a combined turnover of £10.9bn, the North of England has the breadth of business, depth of expertise and investment in specialist infrastructure that rivals anything that any other UK region can offer and the Bionow Awards recognise this success and achievement.

Back to news

London, UK

One Euston Square
40 Melton Street
London, NW1 2FD

t+44 (0) 207 186 8500

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau

t+41 (0) 435 080 781

Munich, Germany

München 5 Höfe
Theatinerstrasse 11
DE- 80333 München

t+49 (0) 89 710 42 2246